Aptorum Group Limited

1.66+0.1150+7.47%Vol 7.61K1Y Perf -71.06%
Nov 29th, 2023 15:27 DELAYED
BID1.53 ASK1.78
Open1.60 Previous Close1.54
Pre-Market- After-Market1.66
 - -  0.01 0.30%
Target Price
8.00 
Analyst Rating
— 0.00
Potential %
383.38 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★+     42.14
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★+     53.19
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
3.86 
Earnings Rating
Neutral
Market Cap6.90M 
Earnings Date
29th Jul 2022
Alpha-0.04 Standard Deviation0.26
Beta-0.11 

Today's Price Range

1.551.80

52W Range

1.369.00

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
3.44%
1 Month
-2.65%
3 Months
-28.66%
6 Months
-46.61%
1 Year
-71.06%
3 Years
-93.73%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
APM1.660.11507.47
AAPL189.37-1.0300-0.54
GOOG136.40-2.2200-1.60
MSFT378.85-3.8500-1.01
XOM102.34-1.5600-1.50
WFC43.780.41000.95
JNJ152.110.48000.32
FB196.640.99000.51
GE118.860.01000.01
JPM154.320.78000.51
Financial StrengthValueIndustryS&P 500US Markets
0.60
1.10
0.01
0.16
506.70
Leverage Ratio 1.10
ProfitabilityValueIndustryS&P 500US Markets
5.00
-1 814.80
-1 732.50
-
-
RevenueValueIndustryS&P 500US Markets
527.46K
0.04
100.52
-
Earnings HistoryEstimateReportedSurprise %
----
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
12/2023 FY-2.500.00-
12/2024 FY-0.700.00-
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume7.61K
Shares Outstanding4.17K
Shares Float1.70M
Trades Count53
Dollar Volume12.06K
Avg. Volume5.66K
Avg. Weekly Volume1.76K
Avg. Monthly Volume2.27K
Avg. Quarterly Volume12.95K

Aptorum Group Limited (NASDAQ: APM) stock closed at 1.655 per share at the end of the most recent trading day (a 7.47% change compared to the prior day closing price) with a volume of 7.61K shares and market capitalization of 6.90M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 18 people. Aptorum Group Limited CEO is Ian Huen.

The one-year performance of Aptorum Group Limited stock is -71.06%, while year-to-date (YTD) performance is -69.91%. APM stock has a five-year performance of %. Its 52-week range is between 1.36 and 9, which gives APM stock a 52-week price range ratio of 3.86%

Aptorum Group Limited currently has a PE ratio of -1.90, a price-to-book (PB) ratio of 0.87, a price-to-sale (PS) ratio of 12.08, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -41.70%, a ROC of -36.63% and a ROE of -42.99%. The company’s profit margin is -%, its EBITDA margin is -1 732.50%, and its revenue ttm is $527.46 Thousand , which makes it $0.04 revenue per share.

Of the last four earnings reports from Aptorum Group Limited, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Aptorum Group Limited’s next earnings report date is -.

The consensus rating of Wall Street analysts for Aptorum Group Limited is (0), with a target price of $8, which is +383.38% compared to the current price. The earnings rating for Aptorum Group Limited stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Aptorum Group Limited has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Aptorum Group Limited has a Sell technical analysis rating based on Technical Indicators (ADX : 20.17, ATR14 : 0.16, CCI20 : -35.87, Chaikin Money Flow : -0.03, MACD : -0.09, Money Flow Index : 27.72, ROC : 1.32, RSI : 41.52, STOCH (14,3) : 51.43, STOCH RSI : 0.45, UO : 66.18, Williams %R : -48.57), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Aptorum Group Limited in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
1 (100.00 %)
Moderate Buy
0
0
0 (0.00 %)
Hold
0
0
0 (0.00 %)
Moderate Sell
0
0
0 (0.00 %)
Strong Sell
0
0
0 (0.00 %)
Summary Rating-
0.00
-
0.00
Strong Buy
1.00

Aptorum Group Limited

Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. Its lead projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.

CEO: Ian Huen

Telephone: +44 2080929299

Address: 17 Hanover Square, London W1S 1BN, , GB

Number of employees: 18

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

57%43%

Bearish Bullish

60%40%

Bearish Bullish

63%37%

 

News

Stocktwits